These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30994802)

  • 41. Visceral leishmaniasis treated with liposomal amphotericin B.
    Catania S; Aiassa C; Tzahtzoglou S; Catania N; Tucciarone L; Antimi A; Ragni G; Clerico A
    Pediatr Infect Dis J; 1999 Jan; 18(1):73-4. PubMed ID: 9951989
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
    Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-dose liposomal amphotericin B for visceral leishmaniasis.
    Kshirsagar NA
    Lancet Glob Health; 2014 Apr; 2(4):e203. PubMed ID: 25103058
    [No Abstract]   [Full Text] [Related]  

  • 47. Different liposomal amphotericin B formulations for visceral leishmaniasis.
    Dorlo TP; Balasegaram M
    Lancet Glob Health; 2014 Aug; 2(8):e449. PubMed ID: 25103515
    [No Abstract]   [Full Text] [Related]  

  • 48. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
    Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
    Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
    Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
    Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
    Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C
    BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995-2009).
    Petrela R; Kuneshka L; Foto E; Zavalani F; Gradoni L
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different liposomal amphotericin B formulations for visceral leishmaniasis--author's reply.
    Kshirsagar N
    Lancet Glob Health; 2014 Aug; 2(8):e450. PubMed ID: 25103516
    [No Abstract]   [Full Text] [Related]  

  • 54. Liposomal amphotericin B as a treatment for human leishmaniasis.
    Balasegaram M; Ritmeijer K; Lima MA; Burza S; Ortiz Genovese G; Milani B; Gaspani S; Potet J; Chappuis F
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):493-510. PubMed ID: 23167833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
    Beltrame A; Arzese A; Camporese A; Rorato G; Crapis M; Tarabini-Castellani G; Boscutti G; Pizzolitto S; Calianno G; Matteelli A; Di Muccio T; Gramiccia M; Viale P
    J Travel Med; 2008; 15(5):358-60. PubMed ID: 19006511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
    Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
    Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characteristics and spatial distribution of Visceral leishmaniasis in children in São Paulo state: an emerging focus of Visceral leishmaniasis in Brazil.
    Naufal Spir PR; Prestes-Carneiro LE; Fonseca ES; Dayse A; Giuffrida R; D'Andrea LA
    Pathog Glob Health; 2017 Mar; 111(2):91-97. PubMed ID: 28221822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.